2019 Novel Coronavirus Disease (COVID-19)

Last Updated: 4/3/20 8:00 AM EST

The 2019 novel coronavirus disease (COVID-19) is a new virus of global health significance caused by infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is thought to spread from person to person in close contact through respiratory droplets.On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic.

Information About Laboratory Testing

Our priority remains in the health and safety of our employees, and the healthcare providers and patients we serve. COVID-19 testing is imperative in aiding healthcare provider to identify infected patients more quickly, and BioReference has been working expeditiously to develop and offer a test that will yield high quality and accurate results.

BioReference offers a real-time reverse-transcription polymerase chain reaction (real-time RT-PCR) assay, to ensure patients and providers have greater access to testing to promote earlier diagnosis and help limit spread of infection.

  • If you are a patient seeking additional information about COVID-19 testing, please click here.
  • If you are a healthcare provider seeking ordering information about COVID-19 testing, please click here.
  • To read the most recent news about testing availability, click here.

COVID-19 Response

In response to the COVID-19 global pandemic, BioReference has completed the following to help support patients, providers and government agencies:

  • Launched nationwide availability of a Real-Time Reverse Transcription Polymerase Chain Reaction (Real-Time RT-PCR) assay to aid healthcare providers in quickly and efficiently diagnosing patients. Read the press release here. 
  • Increased laboratory testing capacity to ensure patients and providers have greater access to testing – currently can accommodate in excess of 20,000 COVID-19 tests per day. Read the press release here. 
  • Collaborated with the New York State Department of Health and Governor Andrew M. Cuomo to provide testing for the first public drive-through testing facility on the East Coast, located in New Rochelle, NY, the epicenter for the New York State outbreak. Additional satellite testing sites to be set-up in the coming weeks. Read the Governor’s Office statement here. 
  • Collaborated with the New York City Health and Hospital Corporation (NYC Health + Hospitals) to provide coronavirus disease 2019 (COVID-19) testing to patients within the more than 70 care locations across the city’s five boroughs. Read the press release here. 
  • Collaborated with the State of New Jersey to provide COVID-19 testing across the state, including access at the first five NJ drive-through testing facilities in the counties of Burlington, Essex, Hudson, Ocean and Union.  Read the press release here. 
  • Collaborated with the City of Detroit to provide COVID-19 testing at drive-through locations for residents by appointment. Read the press release here. 
  • Collaborated with the City of Miami to provide COVID-19 testing for Miami residents by appointment, and collaborated with Larkin Community Hospital to offer drive-through testing centers in South Florida, Hialeah and Hollywood, FL. Read the press release here. 
  • Joined NYC Mayor de Blasio during NY City Hall press conference to discuss expanded testing throughput in support of the NYC public health system, highlighting how the private sector can assist with government agencies to help combat this epidemic. Watch the press conference here. 
  • Joinined the New Jersey Governor Phil Murphy at a press conference in Bergen County to discuss COVID-19 testing and state operated drive-through testing sites. Watch the press conference here. 
  • Attended a meeting with Vice President Mike Pence, members of the White House’s Coronavirus Task Force, The American Clinical Laboratory Association (ACLA) and other diagnostic laboratory leaders from across the nation to discuss the critical issues related to coronavirus disease testing capacity as the demand for testing in America grows. Read the ACLA statement here.

Frequently Asked Questions

The CDC provides many resources for providers and others to help guide the evaluation and management of patients. Please click here to access a general list of frequently asked questions pertaining to COVID-19.

We continue to closely monitor and respond to this rapidly evolving situation. Please continue to visit this page for the most up-to-date information or call 833-684-0508.

Healthcare providers should notify their local or state health department immediately in the event of a patient under investigation for COVID-19. Patients should call their state’s COVID-19 hotline with any state-by-state questions. Please visit the CDC website for more information here.

On Tuesday, March 10, 2020, members of the BioReference leadership team held a call to update our health plan colleagues regarding the efforts BioReference is undertaking in response to this outbreak. To receive a recording of this call, click “Request”